Search company, investor...

Genicon Sciences Corporation


Series C - II | Alive

Total Raised


Last Raised

$32.6M | 22 yrs ago

About Genicon Sciences Corporation

Genicon Sciences Corporation (Now part of Invitrogen) Genicon Sciences is a company providing assay solutions to the biotechnology, genomics, proteomics and clinical diagnostics industries. The company's Resonance Light Scattering (RLS) technology is a patented, ultra-sensitive signal generation platform for the simple and efficient detection, measurement and analysis of biological interactions. RLS technology aims to utilize the Resonance Light Scattering properties of nano-size particles that can be used on various test formats including microarray, microfluidics, membranes and HTS formats.

Headquarters Location

11535 Sorrento Valley Rd.

San Diego, California, 92121,

United States

Missing: Genicon Sciences Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Genicon Sciences Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Genicon Sciences Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genicon Sciences Corporation is included in 1 Expert Collection, including Omics.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Genicon Sciences Corporation Frequently Asked Questions (FAQ)

  • Where is Genicon Sciences Corporation's headquarters?

    Genicon Sciences Corporation's headquarters is located at 11535 Sorrento Valley Rd., San Diego.

  • What is Genicon Sciences Corporation's latest funding round?

    Genicon Sciences Corporation's latest funding round is Series C - II.

  • How much did Genicon Sciences Corporation raise?

    Genicon Sciences Corporation raised a total of $41.58M.

  • Who are Genicon Sciences Corporation's competitors?

    Competitors of Genicon Sciences Corporation include Brandenburg, MOgene LC, Trellis Bioscience, Array Biopharma, SweTree Technologies and 11 more.

Compare Genicon Sciences Corporation to Competitors

NanoImaging Services Logo
NanoImaging Services

NanoImaging Services aims to provide transmission electron microscopy (TEM) imaging and analysis services to the pharmaceutical, biotechnology and nanotechnology industries.

Diagnostic Technologies

Diagnostic Technologies Ltd. (DTL) is a medical diagnostic and biotechnology company at the forefront of placental protein molecular biology and biochemistry. The company aims to become a major player in managing high risk pregnancies by commercialising a technology platform of versatile biotechnology products for detecting and managing at risk mothers for intrauterine growth restriction, preeclampsia and pre-term delivery. The company focuses on the development of diagnostic tools to aid in the assessment of high-risk pregnancies. In particular, the technology platform focuses on pregnancy related proteomics and genomics to produce specific and sensitive testing kits for the detection of high risk and problem pregnancies.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.


ARCXIS develops, produces, and distributes portable biological diagnostic tools with the ability to analyze, detect, and characterize infectious disease agents. It develops diagnostic tools for use in national defense, clinical diagnostics, as well as food and beverage applications. The company was founded in 2004 and is based in Houston, Texas.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.